Daclatasvir A Drug That Is Listed In The UK And Japan To Treat Hepatitis C

Daclatasvir is a British and Japanese-listed treatment of hepatitis C drugs, the efficacy and treatment cycle and the Bouvet more similar. It is reported that the United States is studying Dhaka's joint drug use, there is no relevant listing news.

The most common adverse reactions (frequency 10% or greater) are headaches and fatigue. The severity of all adverse reactions is mild to moderate. One case of severe adverse events was considered unrelated to Daklinza, and no subjects were terminated for adverse events. The price of Dakatave is more expensive, especially cautious when choosing.

The efficacy of Bouvet in Dhaka combined with that of the two generations is similar to that of the second generation, so what is the cure rate and relapse rate of the Bouvet in Dhaka? Through the clinical trial data of the Dhaka, we also obtained the following data on the cure rate and recurrence rate of the Dhaka Wei, and by comparing the cure rate data of the previous two generations, we can get a clearer picture of the efficacy data of the two drugs.

Hepatitis C Type 1 patients: Dhaka + Grand Bouvet in the treatment of HCV type 1 patients with the efficacy of similar to the second generation, in the cure rate is even higher than the second generation;

Hepatitis C 2 patients: in the treatment cycle of Dhaka 24 weeks, the cure rate can also reach 100%, this data is also higher than the second generation;

Hepatitis C Type 3 patients: Hepatitis C Type 3 is the most difficult to treat a genotype, it is recommended that Hepatitis C 3 patients using the Dhaka combined with Bouvet + ribavirin treatment 24 weeks, the cure rate of the statistics can also reach 100%!

For other HCV genotypes such as genotype 4, although the cure rate can still reach 100%, in fact, the number of patients with less safety statistics, persuasion is not, hepatitis C genotypes such as 4, 5, 6 type of patients are also relatively rare types, so in these genotypes of the statistical data is not much, However, since he was not approved for the hepatitis C 5, type 6, the hepatitis C gene 5 and type 6 were not in the statistical range.

In terms of the therapeutic effects of each genotype, the second and Dhaka United Bouvet in the treatment of hepatitis C Group of hepatitis C genotype 1, no difference, Dhaka scheme slightly occupy Shangfeng (100%VS96%/12 weeks without cirrhosis patients), 1 patients with two programs can be used, basically no differences. Since the Gillette was not approved for use in Gene 2, type 3, the hepatitis C gene 2 and 3 patients recommended the use of the Dhaka + Grand Bouvet program, plus ribavirin, 3 weeks of treatment for hepatitis C 24 recommendations.

Overall, the Dhaka + Grand Bouvet Scheme is slightly superior to the second generation program, however, as a result of the compound preparation, the patient only take a pill a day, while Dhaka + Grand Bouvet program needs to take a pill each day, so the two schemes are similar, patients can according to their genotype, Or according to the doctor's advice to choose their own options.